Reports Q3 revenue $17.5M, consensus $4.52M. “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024. Based on the mutation agnostic differentiation effect observed in our single-agent escalation study, we believe FHD-286 has the potential to be a first-in-class broad-based differentiation therapeutic in AML,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “We also made important progress with our Loxo@Lilly collaboration transitioning the BRM Selective inhibitor program to them.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FHTX:
- Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
- Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
- Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
